TY - JOUR
T1 - The rac activator DOCK2 mediates plasma cell differentiation and IgG antibody production
AU - Ushijima, Miho
AU - Uruno, Takehito
AU - Nishikimi, Akihiko
AU - Sanematsu, Fumiyuki
AU - Kamikaseda, Yasuhisa
AU - Kunimura, Kazufumi
AU - Sakata, Daiji
AU - Okada, Takaharu
AU - Fukui, Yoshinori
N1 - Funding Information:
We thank Jason G. Cyster for his kind permission to use HyHEL10 mice in this study. We also thank to Ayumi Inayoshi, Arisa Aosaka, and Linh Thi Hoai Nguyen for technical assistance. This research was supported by the Leading Advanced Projects for Medical Innovation (LEAP) from Japan Agency for Medical Research and Development (AMED to YF; JP17gm0010001); Grants-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology (MEXT to YF) of Japan; and the Japan Society for the Promotion of Science (JSPS to YF)
Publisher Copyright:
© 2018 Ushijima, Uruno, Nishikimi, Sanematsu, Kamikaseda, Kunimura, Sakata, Okada and Fukui.
PY - 2018/2/16
Y1 - 2018/2/16
N2 - A hallmark of humoral immune responses is the production of antibodies. This process involves a complex cascade of molecular and cellular interactions, including recognition of specific antigen by the B cell receptor (BCR), which triggers activation of B cells and differentiation into plasma cells (PCs). Although activation of the small GTPase Rac has been implicated in BCR-mediated antigen recognition, its precise role in humoral immunity and the upstream regulator remain elusive. DOCK2 is a Rac-specific guanine nucleotide exchange factor predominantly expressed in hematopoietic cells. We found that BCR-mediated Rac activation was almost completely lost in DOCK2-deficient B cells, resulting in defects in B cell spreading over the target cell-membrane and sustained growth of BCR microclusters at the interface. When wild-type B cells were stimulated in vitro with anti-IgM F(ab')2 antibody in the presence of IL-4 and IL-5, they differentiated efficiently into PCs. However, BCR-mediated PC differentiation was severely impaired in the case of DOCK2-deficient B cells. Similar results were obtained in vivo when DOCK2-deficient B cells expressing a defined BCR specificity were adoptively transferred into mice and challenged with the cognate antigen. In addition, by generating the conditional knockout mice, we found that DOCK2 expression in B-cell lineage is required to mount antigen-specific IgG antibody. These results highlight important role of the DOCK2-Rac axis in PC differentiation and IgG antibody responses.
AB - A hallmark of humoral immune responses is the production of antibodies. This process involves a complex cascade of molecular and cellular interactions, including recognition of specific antigen by the B cell receptor (BCR), which triggers activation of B cells and differentiation into plasma cells (PCs). Although activation of the small GTPase Rac has been implicated in BCR-mediated antigen recognition, its precise role in humoral immunity and the upstream regulator remain elusive. DOCK2 is a Rac-specific guanine nucleotide exchange factor predominantly expressed in hematopoietic cells. We found that BCR-mediated Rac activation was almost completely lost in DOCK2-deficient B cells, resulting in defects in B cell spreading over the target cell-membrane and sustained growth of BCR microclusters at the interface. When wild-type B cells were stimulated in vitro with anti-IgM F(ab')2 antibody in the presence of IL-4 and IL-5, they differentiated efficiently into PCs. However, BCR-mediated PC differentiation was severely impaired in the case of DOCK2-deficient B cells. Similar results were obtained in vivo when DOCK2-deficient B cells expressing a defined BCR specificity were adoptively transferred into mice and challenged with the cognate antigen. In addition, by generating the conditional knockout mice, we found that DOCK2 expression in B-cell lineage is required to mount antigen-specific IgG antibody. These results highlight important role of the DOCK2-Rac axis in PC differentiation and IgG antibody responses.
UR - http://www.scopus.com/inward/record.url?scp=85042088785&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042088785&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2018.00243
DO - 10.3389/fimmu.2018.00243
M3 - Article
AN - SCOPUS:85042088785
SN - 1664-3224
VL - 9
JO - Frontiers in Immunology
JF - Frontiers in Immunology
IS - FEB
M1 - 243
ER -